Tagged with Access

Spain Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate managers, and the heads of some of the country’s leading domestic firms. These interviewees’ insights are catalogued in the downloadable…

Singapore On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world’s population. Speaking at the outset…

Italy The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who independently manage the budget for territorial pharmaceutical expenditure and evaluate regional access. According to many industry stakeholders, this lengthy process…

Mexico The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and revenue increases are being seen despite regulatory backlog and medicine shortages due to inefficient handling of the public system. He…

Egypt Takeda Egypt’s Samy Khalil gives an overview of the company’s presence in the country and the fundamentals behind its double-digit growth there, provides his view of the healthcare transformation of the country – both achievements and challenges – and explains why Egypt was added to Takeda’s Access Markets cluster.  …

Egypt Amgen’s country director for the ELI cluster (Egypt, Levant, and Iran), Ahmed Kishta, dives into the dynamics shaping the Egyptian market, Egypt’s Vision 2030 and how Amgen is contributing to the health of Egyptian patients.   The effort to transform healthcare in Egypt has been tremendous during the last 5-6…

Africa Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a swathe of “impact bottlenecks” unaddressed. Hwenda calls for a more holistic approach, moving beyond simply bringing medicines to African countries…

Middle East & Africa Apart from a maturing regulatory environment and the expansion of healthcare coverage across the region, a number of other factors are contributing to the evolution of the MEA pharma market. Results from the second wave of a PhRMA-commisioned IQVIA market access study covering Saudi Arabia (KSA), UAE, Kuwait, Lebanon, Jordan,…

USA While patient groups view the United States’ new Inflation Reduction Act as a positive move towards capping out-of-pocket drug costs for older Americans, the innovative pharma industry, after aggressively lobbying against it, still argues that the new legislation will hamper drug development. [The new law] is a significant step in…

Italy Giuseppe Maduri, Chairman, Managing Director, General Manager Italy, Greece, Cyprus, Malta at Astellas Pharma explains the Japanese company’s focus on unmet needs and how Italy, one of its top European markets, is working to ovecome market access challenges.  Greater anticipation would allow patients’ faster access to innovation but requires a…

Middle East & Africa Within the context of the MEA region’s maturing regulatory environment, the expansion of healthcare coverage and regulatory changes aimed at making the New Molecular Entities (NMEs) review process more efficient, registrations have increased in Saudi Arabia, UAE, Tunisia and Egypt, but slowed down in other territories. Results from the second…

Global Merck Group’s Vice President Global Market Access & Pricing Strategic Planning, Marco Rauland, takes a look at recent advancements in Machine Learning and Artificial Intelligence and how these technologies can offer a sophisticated and flexible approach not only to predicting drug pricing, but also to estimating market access with different…